Tabletting: the issues facing today's manufacturers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tabletting: the issues facing today's manufacturers

Pharmaceutical Technology Europe
Volume 22, Issue 6

The full version of this tabletting feature can be read in the June issue of our digital magazine: http://www.pharmtech.com/ptedigital0610


(TEK IMAGE/SPL/Getty Images)
Compressed tablets are the most popular solid dosage form and, despite having been used for many years, still offer numerous advantages. For instance, they are portable and very simple to use, and can protect unstable medications or disguise unpalatable ingredients. Importantly, the techniques and equipment required to manufacture compressed tablets are very well established, making the process relatively straightforward. Tablets can be manufactured in almost any size, shape and colour, and breakthroughs made over the years have allowed more complex tablets to be manufactured, such as sustained release or fast dissolving formulations, without the need to change current processes and equipment.


Figure 1
The maturity of tabletting technologies was highlighted in a recent PTE survey, where most respondents indicated that tablet manufacture problems could usually be traced back to poor formulation design rather than problems with manufacturing equipment (Figure 1).

As tabletting is so crucial to the pharma industry, we have dedicated this month's special feature to tabletting processes and technologies. Unlike some industries we have studied that have witnessed many innovations in recent years, the tablet manufacturing industry has remained relatively static and still utilises the same methods and technologies that have been around for many years, although in many cases improvements have been made to boost throughput and increase machine flexibility and efficiency.

Although there have been few major innovations, however, this doesn't mean that the industry is not evolving. The sector is seeing a shift in processing methodology as companies seek to implement Quality by Design principles and there is also a growing emphasis on generics. Additionally, the threat of falsified medicines has necessitated the need for coding and identification technologies, as well as sophisticated analytical methods that can distinguish between genuine and counterfeit products.

To find out about the current state of tablet manufacture, PTE spoke to several experts involved in the manufacturing process, including granulation, drying and equipment troubleshooting.

Our full special feature of tabletting technologies, featuring contributions on the subjects of blending, coating, tablet analysis and more, as well as a product showcase of some of the latest equipment and systems, can be accessed at: http://www.pharmtech.com/ptedigital0610/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here